$40 million upfront including $25 million cash and $15 million in equity … Continue reading “Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China”
XF-73 met its primary end point with >99% nasal aureus reduction within 24 hours … Continue reading “XF-73 data abstract to be presented at 2021 ECCMID”
vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the … Continue reading “VASOPHARM ANNOUNCES RESULTS OF THE NOSTRA III TRAUMATIC BRAIN INJURY PHASE III STUDY”
Company co-created and funded by Novo Holdings and HealthCap Breakthrough asset in-licensed … Continue reading “Novo Seeds Launches Tribune Therapeutics to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases”
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused … Continue reading “Positive update on microbiome therapeutic NTCD-M3”
Company co-created and funded by Novo Holdings and HealthCap Breakthrough asset in-licensed … Continue reading “Novo Seeds Launches Tribune Therapeutics to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases”
Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections · Preparations for … Continue reading “Destiny Pharma: Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections”
Executive leadership and strategic focus strengthened for sustained company development 01 June … Continue reading “MACROPHAGE PHARMA APPOINTS DR VENKAT REDDY AS CHIEF EXECUTIVE OFFICER”
Neuraxpharm appoints commercial expert Dr. Maximilian von Wülfing as Chief Operating Officer … Continue reading “Neuraxpharm appoints Dr. Maximilian von Wülfing as COO”
May 28, 2021 CAMBRIDGE, Mass. & LONDON–(BUSINESS WIRE)–May 27, 2021– Centessa Pharmaceuticals … Continue reading “Centessa Announces Pricing of Initial Public Offering”
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that … Continue reading “Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency”
Largest private financing round by an Asia-based life sciences tools company Important … Continue reading “Novo Holdings Leads US$200M Series A investment in Asia-Based Life Sciences Tools Company Esco Lifesciences Group”
Novo Holdings and HBM Partners co-lead round with international investor syndicate Numab … Continue reading “Novo Holdings co-leads oversubscribed CHF 100 Million (USD 110 M) Series C in Numab Therapeutics”
Investment round led by Novo Holdings A/S (“Novo Holdings”), joined by a … Continue reading “Novo Holdings leads US$125 Million Series C in Hummingbird Bioscience”
Company to accelerate industrial scale-up of its high-performance bio-based silk polymers and … Continue reading “Novo Holdings leads EUR 29M investment in bio-based silk supplier AMSilk”
eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing LNP-formulated mRNA immunotherapies as … Continue reading “eTheRNA immunotherapies conference attendance for May- June 2021”
Bionical Emas, a global specialist Clinical Research Organization (CRO), has today announced … Continue reading “Bionical Emas launches Expanded Access Program for JZP458 – a recombinant Erwinia Asparaginase”
£5.3 million financing to complete First-in-Man safety study Led by Mercia, Downing … Continue reading “Invizius announces successful Series A financing to develop anti-inflammatory treatment for haemodialysis”
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that … Continue reading “Calliditas promotes Andrew Udell to President, North America”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
Spitalfields
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
